What question did this study set out to answer?

To evaluate the efficacy and safety of daily topiramate (100 mg/day) compared with placebo for preventive treatment in patients suffering from chronic migraine.

February 1, 2007Headache The Journal of Head and Face Pain

Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Trial

View Full Paper

Ask AI

Bookmark

To evaluate the efficacy and safety of daily topiramate (100 mg/day) compared with placebo for preventive treatment in patients suffering from chronic migraine.
Multicenter, parallel-group, double-blind randomized trial in adults aged 18 to 65 years with at least 15 headache days per month (randomized N=328; intent-to-treat N=306; 153 topiramate, 153 placebo).
Participants received 16 weeks of double-blind treatment with topiramate titrated upward from 25 mg/day to a target of 100 mg/day (or maximum tolerated dose) versus matched placebo.
The primary endpoint was change from baseline in mean monthly migraine/migrainous days analyzed via analysis of covariance using a gatekeeper sequence.
Topiramate significantly reduced mean monthly migraine/migrainous days compared with placebo (-6.4 vs -4.7 days, P=0.010) and mean migraine days (-5.6 vs -4.1 days, P=0.032).
Treatment-emergent adverse events occurred in 82.5% of topiramate subjects and 70.2% of placebo subjects, leading to discontinuation in 10.9% versus 6.1%, respectively.
The most common adverse event with topiramate was paresthesia (28.8% vs placebo), and no serious adverse events or deaths were reported.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized double-blind trial shows topiramate reduces monthly headache days in adults with chronic migraine, indicating its efficacy as a preventive therapy.

Cite This Study

Silberstein et al. (2007) studied this question.

synapsesocial.com/papers/6a7dbefccecc27a187a1495f https://doi.org/10.1111/j.1526-4610.2006.00684.x

View Full Paper

Ask AI

Bookmark

Implication

Randomized double-blind trial shows topiramate reduces monthly headache days in adults with chronic migraine, indicating its efficacy as a preventive therapy.

Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Trial

Key Points

Discussion

Implication

Cite This Study

Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Trial

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider